Valtrax Research is opening — leave your email and we'll ping you the moment the first compounds are listed.
Every lot tested by Janoshik Analytical
Cart
Your cart is empty
Find
Valtrax Research is opening — leave your email and we'll ping you the moment the first compounds are listed.
Your cart is empty
Stabilized GHRH(1-44) analogue · trans-3-hexenoyl cap
A trans-3-hexenoyl-capped GHRH(1-44) analogue that resists the DPP-4 cleavage which clears native GHRH. Supplied as a lyophilized powder for research purposes only.
Catalog opens shortly. Leave your address and we will ping you the moment this compound is orderable.
Tested lot by lot at ≥99% purity. The Janoshik certificate for your lot is emailed with the order.
Everything Valtrax Research ships is bench material for in-vitro work. None of it is a drug, a supplement, a cosmetic, or a medical device, and none of it is intended for human or animal use, ingestion, or administration. Placing an order is your confirmation that you are a qualified researcher buying for lawful research, under every Canadian law and regulation that applies to you.
Take the full 44-residue human GHRH sequence, cap the N-terminus with a trans-3-hexenoyl group, and you get tesamorelin — a near-native analogue that resists the dipeptidyl peptidase-4 cleavage that ordinarily chews up GHRH in minutes. The lipid cap is the only departure from the natural hormone, and it is the part that buys the molecule time on the receptor.
Because it stays so close to native GHRH, it engages the same pituitary receptor and drives endogenous, pulsatile growth-hormone release rather than overriding the axis. That fidelity is what makes it a useful probe of the hypothalamic-pituitary feedback loop.
The work pairs a mechanism with measurable downstream endpoints. Upstream: GHRH-receptor engagement and DPP-4-resistant pharmacokinetics. Downstream: pulsatile GH secretion, IGF-1, and — in the most-cited trials — visceral and hepatic fat. Tesamorelin is studied as the case where preserving native feedback while extending half-life can be observed end to end.
The defining property is fidelity-plus-durability: tesamorelin reproduces the GHRH signal at the pituitary receptor but survives long enough in serum to be measurable, thanks to the hexenoyl cap that blocks DPP-4. Work reads the GH and IGF-1 output that follows, and watches whether normal feedback restraint stays intact.
The published evidence is unusually clinical for a research peptide. Falutz characterized its effect on visceral adipose tissue in HIV-associated lipodystrophy, and Stanley extended the question to hepatic fat — so the literature ties GHRH-receptor activation to downstream fat and IGF-1 endpoints rather than to binding alone.
Tesamorelin began as an exercise in minimal modification: keep human GHRH(1-44) intact, add a single N-terminal acyl group, and solve the one liability that made native GHRH impractical — its near-instant degradation by DPP-4. The hexenoyl cap did exactly that without remodeling the recognition sequence.
It was the first GHRH analogue to clear regulatory review, which is why its record skews toward human metabolic studies and why it serves as a reference point for stabilized-GHRH chemistry.
Falutz, J. et al. (2010). Effects of tesamorelin (TH9507), a growth hormone–releasing factor analogue, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.
PubMedFalutz, J. et al. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab 95(9):4291–4304.
PubMedStanley, T.L. et al. (2019). Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV 6(12):e821–e830.
PubMedEvery lot is tested for identity, purity, and net content, and the certificate is emailed with the order.
Janoshik Analytical, a laboratory Valtrax does not own, runs the testing — identity by mass spectrometry, purity by RP-HPLC at ≥99%. The certificate covering the lot you receive is also emailed with your order.
Same Shelf
